Enzon Pharmaceuticals, Inc. (NASDAQ:ENZN)

CAPS Rating: 3 out of 5

A biopharmaceutical company dedicated to the development and commercialization of therapeutics to treat patients with cancer and adjacent diseases.

Recs

0
Player Avatar mjan706 (60.17) Submitted: 9/22/2008 1:44:10 AM : Outperform Start Price: $7.89 ENZN Score: -28.68

An Icahn portfolio stock.

Report this Post Reply

Featured Broker Partners


Advertisement